1-3 of 3
Frank Fliegert, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)

Marco Gobbi, MD, Federico Caligaris-Cappio, MD, Marco Montillo, MD, Stephanie Vauléon, PhD, Stefan Zöllner, PhD, Thomas Dümmler, PhD, Anna Kruschinski, PhD, Frank Fliegert, MD
Journal: Blood
Blood (2012) 120 (21): 4593.
https://doi.org/10.1182/blood.V120.21.4593.4593
Published: 2012
Journal Articles

Randomized Double Blind Placebo Controlled PK/PD Study On the Effects of a Single Intravenous Dose of the Anti-Hepcidin Spiegelmer Nox-H94 On Serum Iron During Experimental Human Endotoxemia

Lucas van Eijk, MD, Dorine W. Swinkels, MD, PhD, John Aaron, Frank Schwoebel, PhD, Frank Fliegert, MD, Luciana Summo, PharmD PhD, Vauleon Stéphanie, PhD, Coby Laarakkers, BSc, Kai Riecke, MD, Peter Pikkers, MD PhD
Journal: Blood
Blood (2012) 120 (21): 3452.
https://doi.org/10.1182/blood.V120.21.3452.3452
Published: 2012
Journal Articles

Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94.

Kai Riecke, MD, Stefan Zöllner, PhD, Malcolm Boyce, MD, Stephanie Vauléon, PhD, Dorine W. Swinkels, MD, PhD, Thomas Dümmler, PhD, Luciana Summo, PharmD PhD, Coby Laarakkers, BSc, Frank Schwoebel, PhD, Frank Fliegert, MD
Journal: Blood
Blood (2012) 120 (21): 2342.
https://doi.org/10.1182/blood.V120.21.2342.2342
Published: 2012